New drug duo targets rare, aggressive liver cancer in teens and young adults

NCT ID NCT06027086

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two drugs, DRP-104 and durvalumab, is safe and can shrink tumors in people with advanced fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. It will enroll about 27 patients aged 12 and older whose cancer has progressed despite prior immunotherapy. The main goals are to check for side effects and see how many patients' tumors respond to the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins SKCCC
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

FIBROLAMELLAR HEPATOCELLULAR CARCINOMA